Business Wire

CO-ANANDA-SCIENTIFIC

14.3.2023 12:05:44 CET | Business Wire | Press release

Share
University of Nebraska Medical Center and ANANDA Scientific announce First Patient Enrolled in FDA-approved clinical trial for Post-Traumatic Stress Disorder (PTSD)

The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD). (Clinical Trials.gov Identifier NCT05269459)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005182/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Pictured above is principal investigator Matthew Rizzo, MD, FAAN, FANA, and Ananda Scientific CEO Sohail Zaidi. (Photo: Business Wire)

The trial is being led by principal investigator Matthew Rizzo, MD, FAAN, FANA, the Reynolds Professor and Chair of the UNMC Department of Neurological Sciences, chief physician for neurological services at Nebraska Medicine, and chief physician for neurosciences clinical programs at Nebraska Medicine.

“We are very excited to have this important trial underway,” said Dr. Rizzo. “Our collaboration with ANANDA Scientific is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population.”

Dr. Rizzo’s research team includes Jennifer Merickel, PhD, Cognitive Neuroscientist and Assistant Professor in the UNMC Department of Neurological Sciences, and Brigette Soltis-Vaughan, an Advanced Practice Registered Nurse,Clinician and Researcher in the UNMC Department of Psychiatry and Instructor in the UNMC Department of Neurological Sciences.

“Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are very pleased to be partnering with the UNMC’s research team in evaluating our promising drugfor this very debilitating condition.”

This phase II double-blind, placebo-controlled, randomized clinical study is planning to enroll 180 participants to provide rigorous evaluation of the efficacy and safety of Nantheia™ ATL5.

ABOUT NANTHEIA™ ATL5

Nantheia™ ATL5 is an investigational drug that uses cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100mg cannabidiol per softgel capsule.

ABOUT University of Nebraska Medical Center

As Nebraska’s only public academic health sciences center, UNMC is committed to the education of a 21st century health care workforce, to finding cures and treatments for devastating diseases, to providing the best care for patients and to serving the state and its communities through award-winning outreach. UNMC has six colleges, two institutes and a graduate studies program, serving more than 4,400 students in about 90 programs. Researchers at UNMC perform cutting-edge research in neurological sciences, oncology, infectious disease, and other key areas.

ABOUT ANANDA SCIENTIFIC

ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005182/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Infobip's 20-Year Analysis of 3.8 Trillion Messages Reveals Rise of Omnichannel, RCS and AI-Driven Communication19.3.2026 11:45:00 CET | Press release

Analysis of 628 billion interactions in 2025 highlights the shift to conversational experiences, with nearly 98% of traffic now sent by customers using multiple channels AI-first cloud communication platform Infobip has released its Messaging Trends Report 2026, offering an analysis of the state of business communication. Drawing on data from 628 billion mobile interactions in 2025 and a historical review of 3.8 trillion messages over the past 20 years, the report charts the evolution from single-channel messaging to complex, AI-powered omnichannel experiences. The data reveals a shift in how brands engage with customers. While SMS remains a critical pillar for reliability, accounting for 62% of traffic, the growth of rich, conversational channels is accelerating. RCS traffic grew 3x globally last year, with 70x increase in North America. WhatsApp continues to dominate the conversational landscape, facilitating 91% of all conversational AI interactions on the platform, marking a 25% in

REPLY Unveils the New Editions of the Reply AI Music Contest and Reply AI Film Festival under the Theme “Imaginatio Nova”19.3.2026 09:00:00 CET | Press release

This year once again, the top finalists of the music contest will perform live on stage at Kappa FuturFestival in Turin, while the finalists of the film contest will be invited to an event organised by Reply and Mastercard, to be held in September in Venice. Reply [EXM, STAR: REY, ISIN: IT0005282865] confirms its commitment for 2026 to fostering dialogue between creativity, technology and artificial intelligence through the Reply AI Music Contest and the Reply AI Film Festival, the two international AI competitions open to creatives, filmmakers, musicians and innovation professionals from around the world. The theme of the 2026 edition, “Imaginatio Nova”, is an invitation to explore a new phase of imagination, where human creativity is renewed through technology. This approach views artificial intelligence not as a substitute for artistic talent, but as a catalyst for new visions, languages and expressive possibilities, capable of generating forms that did not previously exist. This pr

Valeo Foods Group Accelerates Growth in Eastern Europe With Acquisition of Prestige-96, a Leading Bulgarian Sweet Baked Goods Player19.3.2026 08:00:00 CET | Press release

Valeo Foods Group, one of Europe’s leading producers of sweets, treats and snacks, today announced that it has reached an agreement to acquire 100% of Prestige-96 AD (“Prestige”), a market-leading Bulgarian manufacturer of sweet baked goods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319225232/en/ Prestige-96 sandwich biscuits. Founded in 1996, Prestige is one of Bulgaria’s most established and trusted producers of biscuits, wafers and sweet snack products. Its portfolio features some of the country’s most recognisable local brands including - Naya (Ная), Hyper (Хайпър), Mirage (Мираж) and Roden Kray (Роден Край). Prestige employs approximately 450 people across its operations. The acquisition marks a significant milestone in Valeo Foods Group’s long-term growth strategy, focused on acquiring market-leading, iconic local brands as part of its continued European expansion. As Valeo Foods Group’s eighth acquisition sinc

SymphonyAI AI Platforms Deployed for Compliance Environment at Munich Re19.3.2026 07:32:00 CET | Press release

Advanced, intelligence-driven technology supports sanctions screening and AML at global scale As regulatory expectations grow more complex and financial crime risks continue to evolve, SymphonyAI, a global leader in Vertical AI platforms, offers a centralized, enterprise-grade technology foundation designed to operate at global scale while meeting local regulatory requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319144999/en/ SymphonyAI supports Munich Re, one of the leading reinsurers, and subsidiaries through its financial crime platform, which combines domain-specific expertise with artificial intelligence to help financial institutions detect, investigate, and manage financial crime risk with greater precision and efficiency. “Integrated, production-scale financial crime platforms that can evolve with the risk landscape,” said John Edison, President of Financial Services, SymphonyAI. “Our work together wit

Royal Moroccan Football Federation Acknowledges Decision Rendered by the CAF Appeals Committee18.3.2026 18:49:00 CET | Press release

The Royal Moroccan Football Federation (FRMF) wishes to reiterate that its appeal was never aimed at contesting the sporting merit or performance of the teams involved in this tournament, but solely to ensure the proper enforcement of competition regulations. The federation reaffirms its commitment to respecting the regulations, ensuring the clarity of the competitive framework and maintaining the stability of African football competitions. The Federation also wishes to commend all the nations that participated in this year’s edition of the Africa Cup of Nations (AFCON), which served as a significant moment for African football. The FRMF will issue a more comprehensive official statement in the coming days after a scheduled meeting of its governing bodies. Source: AETOSWire View source version on businesswire.com: https://www.businesswire.com/news/home/20260318763307/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye